ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
BG Medicine Inc (CE)

BG Medicine Inc (CE) (BGMD)

0,000001
0,00
( 0,00% )
Aktualisiert: 01:00:00

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Current Price
0,000001
Gebot
0,00
Fragen
0,00
Volumen
-
0,00 Tagesbereich 0,00
0,000001 52-Wochen-Bereich 0,00013
Handelsende
0,000001
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
-
Durchschnittliches Volumen (3 Mio.)
29.024
Finanzvolumen
-
VWAP
-

BGMD Neueste Nachrichten

Automated Galectin-3 Blood Test Launch - Report on BG Medicine

Automated Galectin-3 Blood Test Launch - Report on BG Medicine PR Newswire NEW YORK, July 21, 2015 NEW YORK, July 21, 2015 /PRNewswire/ -- ACI Association has initiated research coverage on BG...

BG Medicine Reports First Quarter 2015 Financial Results

Net Loss Reduced by 38% and Operating Cash Burn Cut by 42% from First Quarter 2014 Outlook Improved for 2015 WALTHAM, Mass., May 14, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc...

BG Medicine Announces Q1 2015 Financial Results Release Date and Conference Call Information

WALTHAM, Mass., May 7, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced that the company will host a conference call and webcast on Thursday, May 14, 2015 at 8:30 a.m...

BG Medicine Submits 510(k) to FDA for Additional Indication for the BGM Galectin-3(R) Test

WALTHAM, Mass., March 31, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today reported that it has filed a 510(k) Premarket...

BG Medicine Reports 2014 Fourth Quarter and Year End Financial Results

Net Loss Reduced by 49% and Operating Cash Burn Cut by 47% From 2013 First Automated Galectin-3 Testing Expected to Launch in U.S. in Mid-2015 WALTHAM, Mass., March 31, 2015 (GLOBE...

BG Medicine Welcomes Major Publication on the BioImage Study in the Journal of the American College of Cardiology

WALTHAM, Mass., March 26, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today the publication of a landmark study, in the Journal of the American College of Cardiology...

BG Medicine Announces Fiscal Year 2014 Financial Results Release Date and Conference Call Information

WALTHAM, Mass., March 24, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced that the company will host a conference call and webcast on Tuesday, March 31, 2015 at 8:30 am...

BG Medicine Announces Receipt of NASDAQ Notice of Non-Compliance; Intends to Request Hearing and Seek Extension

WALTHAM, Mass., March 13, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) (the "Company"), the developer of the BGM Galectin-3® Test, today announced its receipt of a notice of...

BG Medicine Announces Receipt of Favorable NASDAQ Listing Determination

WALTHAM, Mass., Feb. 2, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, announced today its receipt of a favorable decision from the...

BG Medicine Reports First Quarter 2014 Financial Results

Net Loss Reduced by 60% and Operating Cash Burn Cut by 44% From First Quarter 2013 Continued Progress Made Toward Delivering on Critical Catalysts for Growth WALTHAM, Mass., May 14, 2014...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1001.0E-61.0E-61.0E-6985001.0E-6CS
4001.0E-61.0E-61.0E-6501881.0E-6CS
12001.0E-61.0E-61.0E-6290241.0E-6CS
26001.0E-60.000131.0E-6160551.1E-6CS
52001.0E-60.000131.0E-6130451.1E-6CS
156001.0E-60.021.0E-6101050.00016266CS
260-0.007999-99.98750.0080.2571.0E-6164450.04808226CS

BGMD - Frequently Asked Questions (FAQ)

What is the current BG Medicine (CE) share price?
The current share price of BG Medicine (CE) is US$ 0,000001
What is the 1 year trading range for BG Medicine (CE) share price?
BG Medicine (CE) has traded in the range of US$ 0,000001 to US$ 0,00013 during the past year
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
DTEMFDitem Explorations (CE)
US$ 0,01
(999.900,00%)
1.000
RRMLFRoss River Minerals Inc (CE)
US$ 0,0089
(889.900,00%)
9,95k
SDCCQSmileDirectClub Inc (CE)
US$ 0,0003
(29.900,00%)
356,08k
PRMDPrimeMD Inc (CE)
US$ 0,0002
(19.900,00%)
100
COUVCorporate Universe Inc (CE)
US$ 0,0002
(19.900,00%)
73,97k
RAHGFRoan Holdings Group Company Ltd (CE)
US$ 0,000001
(-99,99%)
200
UBMRFUrbanimmersive Inc (CE)
US$ 0,000001
(-99,97%)
1,5k
UNDRUnderSea Recovery Corporation (CE)
US$ 0,000001
(-99,90%)
55k
ERHEERHC Energy Inc (CE)
US$ 0,000001
(-99,88%)
407
EICCFE Automotive Inc (CE)
US$ 0,0001
(-99,88%)
5,67k
PHILPHI Group Inc (PK)
US$ 0,00045
(-10,00%)
464,92M
GRLFGreen Leaf Innovations Inc (PK)
US$ 0,0002
(100,00%)
171,04M
HMBLHUMBL Inc (PK)
US$ 0,00085
(6,25%)
134,76M
RDARRaadr Inc (PK)
US$ 0,0016
(-5,88%)
120,97M
CGACCode Green Apparel Corp (PK)
US$ 0,0004
(-11,11%)
110,87M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock